{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:10:47Z","timestamp":1793286647965,"version":"4.5.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T00:00:00Z","timestamp":1662422400000},"content-version":"vor","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic and Interventional Imaging"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.diii.2021.04.004","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T10:00:57Z","timestamp":1619517657000},"page":"515-523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["PET\/CT in the management of differentiated thyroid cancer"],"prefix":"10.1016","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8787-731X","authenticated-orcid":false,"given":"Emilia","family":"Zampella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Klain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-543X","authenticated-orcid":false,"given":"Leonardo","family":"Pace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3431-7658","authenticated-orcid":false,"given":"Alberto","family":"Cuocolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diii.2021.04.004_bib0480","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1210\/jc.2005-1322","article-title":"Survival and death causes in differentiated thyroid carcinoma","volume":"91","author":"Eustatia-Rutten","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diii.2021.04.004_bib0485","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/thy.2010.0178","volume":"20","author":"Tuttle","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0490","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1210\/jcem.87.4.8338","article-title":"Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?","volume":"87","author":"Mazzaferri","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diii.2021.04.004_bib0495","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/EJE-13-0524","article-title":"Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma","volume":"170","author":"Jeon","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0500","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1102\/1470-7330.2010.0002","article-title":"Molecular imaging in thyroid cancer","volume":"10","author":"Heston","year":"2010","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0505","doi-asserted-by":"crossref","first-page":"938","DOI":"10.2967\/jnumed.108.051276","article-title":"Dual-modality imaging: combining anatomy and function","volume":"49","author":"Townsend","year":"2008","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0510","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: the metabolic requirements of cell proliferation","volume":"324","author":"Vander Heiden","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.diii.2021.04.004_bib0515","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/RLU.0b013e3182393599","article-title":"Glucose transporter 1 expression, tumor proliferation, and iodine\/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma","volume":"37","author":"Grabellus","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0520","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1089\/105072502760339307","article-title":"Glucose transporter 1 gene expression is related to thyroid neoplasm with an unfarovable prognosis: an immunohistochemical study","volume":"12","author":"Schonberger","year":"2002","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0525","first-page":"910","article-title":"Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose","volume":"28","author":"Joensuu","year":"1987","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0535","first-page":"1468","article-title":"Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer","volume":"37","author":"Feine","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0540","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.crad.2005.05.018","article-title":"PET\/CT in oncology: a major advance","volume":"60","author":"Wechalekar","year":"2005","journal-title":"Clin Radiol"},{"key":"10.1016\/j.diii.2021.04.004_bib0545","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.diii.2019.07.006","article-title":"18F-FDG PET\/CT in pancreatic adenocarcinoma: a role at initial imaging staging?","volume":"100","author":"Wartski","year":"2019","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0550","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.diii.2019.11.001","article-title":"18F-FDG PET\/CT in pancreatic adenocarcinoma: on the edge of a paradigm shift?","volume":"100","author":"Palmieri","year":"2019","journal-title":"Diagn Interv Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0555","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1056\/NEJM199801293380506","article-title":"Papillary and follicular thyroid carcinoma","volume":"338","author":"Schlumberger","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0560","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/EJE-16-0360","article-title":"The role of FDG PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice","volume":"175","author":"Kukulska","year":"2016","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0565","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/cncr.23515","article-title":"Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose positron emission tomography-positive thyroid carcinoma","volume":"113","author":"Rivera","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.diii.2021.04.004_bib0570","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/thy.1997.7.363","article-title":"GLUT1 glucose transporter expression in benign and malignant thyroid nodules","volume":"7","author":"Haber","year":"1997","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0575","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2265.2007.03008.x","article-title":"Molecular characteristics in papillary thyroid cancers (PTCs) with no 131 I uptake","volume":"68","author":"Mian","year":"2008","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0580","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-09-0727","article-title":"Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1","volume":"69","author":"Ricarte-Filho","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.diii.2021.04.004_bib0585","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1210\/jc.2012-2390","article-title":"Diagnostic and clinical significance of F-18-FDG PET\/CT thyroid incidentalomas","volume":"97","author":"Bertagna","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.diii.2021.04.004_bib0590","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12149-009-0299-4","article-title":"Incidental thyroid uptake on F-18-FDG PET\/CT: correlation with ultrasonography and pathology","volume":"23","author":"Kang","year":"2009","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0595","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.otohns.2007.02.037","article-title":"Incidence of thyroid carcinoma in fluorodeoxyglucose positron emission tomography-positive thyroid incidentalomas","volume":"137","author":"King","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.diii.2021.04.004_bib0600","first-page":"153","article-title":"The clinical relevance of thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography","volume":"16","author":"Hsieh","year":"2018","journal-title":"Ann Nucl Med Sci"},{"key":"10.1016\/j.diii.2021.04.004_bib0605","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40463-017-0200-8","article-title":"Thyroid incidentalomas on 18FDG PET\/CT: a metabolico-pathological correlation","volume":"46","author":"Hagenimana","year":"2017","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.diii.2021.04.004_bib0610","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1177\/0194599814530861","article-title":"The proportion of malignancy in incidental thyroid lesions on 18-FDG PET study: a systematic review and meta-analysis","volume":"151","author":"Nayan","year":"2014","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.diii.2021.04.004_bib0615","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2011.04005.x","article-title":"18FDG-positron emission tomography\/computed tomography (PET\/CT) scanning in thyroid nodules with nondiagnostic cytology","volume":"74","author":"Giovanella","year":"2011","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0620","doi-asserted-by":"crossref","first-page":"840","DOI":"10.3906\/sag-1503-26","article-title":"The incidence of 18F-FDG PET\/CT thyroid incidentalomas and the prevalence of malignancy: a prospective study","volume":"46","author":"\u015eencan Eren","year":"2016","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.diii.2021.04.004_bib0625","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/RLU.0b013e318125037a","article-title":"F-18-FDG PET\/CT in the management of thyroid cancer","volume":"32","author":"Iagaru","year":"2007","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0630","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s40618-020-01244-2","article-title":"FNA indication according to ACR-TIRADS, EU-TIRADS and K-TIRADS in thyroid incidentalomas at 18F-FDG PET\/CT","volume":"43","author":"Trimboli","year":"2020","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.diii.2021.04.004_bib0635","first-page":"100","article-title":"Diagnostic role of F-18-FDG PET\/CT for preoperative lymph node staging in thyroid cancer patients: a systematic review and meta-analysis","volume":"66","author":"Kim","year":"2021","journal-title":"Clin Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0640","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/j.semnuclmed.2006.03.002","article-title":"Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer","volume":"36","author":"Lind","year":"2006","journal-title":"Semin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0645","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12149-011-0559-y","article-title":"FDG PET performed concurrently with initial I-131 ablation for differentiated thyroid cancer","volume":"26","author":"Iwano","year":"2012","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0650","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.2967\/jnumed.112.117119","article-title":"Clinical utility of 18F-FDG PET\/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients","volume":"54","author":"Lee","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0655","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2014.0320","article-title":"Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography\/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer","volume":"25","author":"Nascimento","year":"2015","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0660","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00259-012-2065-4","article-title":"18F-FDG PET\/CT changes therapy management in high-risk DTC after first radioiodine therapy","volume":"39","author":"Rosenbaum-Krumme","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0665","doi-asserted-by":"crossref","first-page":"4352","DOI":"10.1038\/s41598-018-22656-4","article-title":"Predicting 131I-avidity of metastases from differentiated thyroid cancer using 18F-FDG PET\/CT in postoperative patients with elevated thyroglobulin","volume":"8","author":"Liu","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.diii.2021.04.004_bib0670","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1530\/EJE-07-0903","article-title":"The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer","volume":"158","author":"Alzahrani","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0675","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/RLU.0000000000000699","article-title":"FDG PET performed at thyroid remnant ablation has a higher predictive value for long-term survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake","volume":"40","author":"Gaertner","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0680","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/RLU.0000000000000621","article-title":"Prognostic role of 18F-FDG PET\/CT in the postoperative evaluation of differentiated thyroid cancer patients","volume":"40","author":"Pace","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0685","doi-asserted-by":"crossref","first-page":"600","DOI":"10.4158\/EP12047.CO","article-title":"Recurrent differentiated thyroid cancer","volume":"18","author":"Shaha","year":"2012","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diii.2021.04.004_bib0690","first-page":"598","article-title":"Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma","volume":"37","author":"Schlumberger","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0695","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hed.23881","article-title":"Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative (131) I whole-body scan results: a meta-analysis","volume":"38","author":"Caetano","year":"2016","journal-title":"Head Neck"},{"key":"10.1016\/j.diii.2021.04.004_bib0700","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1177\/0284185115594645","article-title":"F18-FDG PET for recurrent differentiated thyroid cancer: a systematic meta-analysis","volume":"57","author":"Haslerud","year":"2016","journal-title":"Acta Radiol"},{"key":"10.1016\/j.diii.2021.04.004_bib0705","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000481707","article-title":"Positron emission tomography (PET) and PET\/CT in thyroid cancer: a systematic review and meta-analysis","volume":"7","author":"Sch\u00fctz","year":"2018","journal-title":"Eur Thyroid J"},{"key":"10.1016\/j.diii.2021.04.004_bib0710","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF00837630","article-title":"Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer","volume":"23","author":"Gr\u00fcnwald","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0715","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4158\/EP-2017-0080","article-title":"The relationship of BRAFV600E mutation status to FDG PET\/CT avidity in thyroid cancer: a review and meta-analysis","volume":"24","author":"Santhanam","year":"2018","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diii.2021.04.004_bib0720","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/MNM.0b013e32832dcfa7","article-title":"Value of 18F-FDG PET\/PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan: a meta-analysis","volume":"30","author":"Dong","year":"2009","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.diii.2021.04.004_bib0725","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/ERC-17-0341","article-title":"Diagnostic performance of PET in thyroid cancer with elevated anti-Tg Ab","volume":"25","author":"Kim","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.diii.2021.04.004_bib0730","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1530\/EJE-10-0256","article-title":"The role of TSH for 18F-FDG PET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis","volume":"163","author":"Ma","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0735","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12020-015-0708-5","article-title":"The role of early 18F-FDG PET\/CT in therapeutic management and ongoing risk stratification of high\/intermediate-risk thyroid carcinoma","volume":"51","author":"Trivi\u00f1o Ib\u00e1\u00f1ez","year":"2016","journal-title":"Endocrine"},{"key":"10.1016\/j.diii.2021.04.004_bib0740","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/thy.2011.0177","article-title":"Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent\/recurrent thyroid carcinoma in intermediate-to-high-risk patients following initial radioactive iodine ablation therapy","volume":"22","author":"Kim","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0745","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/j.clon.2012.08.002","article-title":"Effect of (18)F-fluorodeoxyglucose positron emission tomography\/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses","volume":"24","author":"Dennis","year":"2012","journal-title":"Clin Oncol"},{"key":"10.1016\/j.diii.2021.04.004_bib0750","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1677\/ERC-10-0233","article-title":"Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?","volume":"18","author":"Deandreis","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.diii.2021.04.004_bib0755","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/1754-9485.12286","article-title":"Fluorodeoxyglucose positron emission tomography\/computerized tomography in differentiated thyroid cancer management: importance of clinical justification and value in predicting survival","volume":"59","author":"Marcus","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.diii.2021.04.004_bib0760","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/RLU.0b013e31825b2057","article-title":"Prognostic significance of FDG PET\/CT on the follow-up of patients of differentiated thyroid carcinoma with negative iodine-131 whole-body scan and elevated thyroglobulin levels","volume":"37","author":"Vural","year":"2012","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0765","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/RLU.0000000000000780","article-title":"Prognostic value of (18)F-FDG PET\/CT metabolic parameters in metastatic differentiated thyroid cancers","volume":"40","author":"Masson-Deshayes","year":"2015","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0770","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1007\/s00259-016-3551-x","article-title":"The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer","volume":"44","author":"Terroir","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0775","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fendo.2019.00146","article-title":"Outcome of patients with differentiated thyroid cancer treated with 131-Iodine on the basis of a detectable serum thyroglobulin level after initial treatment","volume":"10","author":"Klain","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0780","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/RLU.0b013e3181b7d95c","article-title":"F-18 FDG PET\/CT evaluation of patients with differentiated thyroid cancer with negative I-131 total body scan and high thyroglobulin level","volume":"34","author":"Bertagna","year":"2009","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0785","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1089\/thy.2012.0081","article-title":"Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels","volume":"22","author":"Leboulleux","year":"2012","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0790","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1089\/thy.2013.0427","article-title":"Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?","volume":"24","author":"Rosario","year":"2014","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0795","first-page":"2","article-title":"Fluorodeoxyglucose PET\/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation","volume":"52","author":"Salvatore","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0800","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s40336-017-0254-7","article-title":"The current and evolving role of FDG\u2013PET\/CT in personalized iodine-131 therapy of differentiated thyroid cancer","volume":"5","author":"Pace","year":"2017","journal-title":"Clin Transl Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0805","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/hed.21791","article-title":"Relationship between serum thyroglobulin and 18FDG PET\/CT in 131I-negative differentiated thyroid carcinomas","volume":"34","author":"Giovanella","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.diii.2021.04.004_bib0810","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s00259-013-2370-6","article-title":"Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET\/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma","volume":"40","author":"Giovanella","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0815","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00259-020-04992-8","article-title":"Thyroglobulin doubling time offers a better threshold than thyroglobulin level for selecting optimal candidates to undergo localizing [18F]FDG PET\/CT in non-iodine avid differentiated thyroid carcinoma","volume":"48","author":"Albano","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0820","first-page":"1557","article-title":"Quantitative imaging of iodine-124 with PET","volume":"37","author":"Pentlow","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0825","first-page":"30","article-title":"The role of (124)I-PET in diagnosis and treatment of thyroid carcinoma","volume":"52","author":"Lubberink","year":"2008","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0830","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/cen.13306","article-title":"Utility of I-124 PET\/CT in identifying radioiodine avid lesions in differentiated thyroid cancer: a systematic review and meta-analysis","volume":"86","author":"Santhanam","year":"2017","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.diii.2021.04.004_bib0835","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00259-007-0660-6","article-title":"The diagnostic value of 124I-PET in patients with differentiated thyroid cancer","volume":"35","author":"Phan","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0840","first-page":"536","article-title":"The effectiveness of 124I-PET\/CT in patients with differentiated thyroid cancer","volume":"53","author":"Capoccetti","year":"2009","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0845","first-page":"1","article-title":"124-I PET\/CT images of differentiated thyroid cancer patients","volume":"51","author":"Rosenbaum-Krumme","year":"2012","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.diii.2021.04.004_bib0850","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/thy.2009.0430","article-title":"(124)I positron emission tomography versus (131)I planar imaging in the identification of residual thyroid tissue and\/or metastasis in patients who have well-differentiated thyroid cancer","volume":"20","author":"Van Nostrand","year":"2010","journal-title":"Thyroid"},{"key":"10.1016\/j.diii.2021.04.004_bib0855","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1007\/s00259-007-0634-8","article-title":"Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET\/CT and FDG PET","volume":"35","author":"Freudenberg","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0860","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.108.060442","article-title":"Identification of a shine-through artifact in the trachea with (124)I PET\/CT","volume":"50","author":"Abdul-Fatah","year":"2009","journal-title":"J Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0865","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1007\/s00259-007-0601-4","article-title":"Disseminated iodine avid lung metastases in differentiated thyroid cancer: a challenge to 124I-PET","volume":"35","author":"Freudenberg","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0870","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1160\/nukmed-0076","article-title":"124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact","volume":"46","author":"Freudenberg","year":"2007","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.diii.2021.04.004_bib0875","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1007\/s00259-008-0761-x","article-title":"EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy","volume":"35","author":"Lassmann","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0880","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","article-title":"EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry","volume":"37","author":"Hindorf","year":"2010","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0885","doi-asserted-by":"crossref","first-page":"235","DOI":"10.23736\/S1824-4785.19.03201-1","article-title":"The role of 124I-PET\/CT lesion dosimetry in differentiated thyroid cancer","volume":"63","author":"Weber","year":"2019","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0890","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s12032-017-1051-x","article-title":"Molecular imaging of advanced thyroid cancer: iodinated radiotracers and beyond","volume":"34","author":"Santhanam","year":"2017","journal-title":"Med Oncol"},{"key":"10.1016\/j.diii.2021.04.004_bib0895","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.7150\/thno.24997","article-title":"[18F]Tetrafluoroborate ([18F]TFB) and its analogs for PET imaging of the sodium\/iodide symporter","volume":"8","author":"Jiang","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.diii.2021.04.004_bib0900","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/RLU.0000000000001977","article-title":"Initial clinical investigation of [18F]tetrafluoroborate PET\/CT in comparison to [124I]iodine PET\/CT for imaging thyroid cancer","volume":"43","author":"Samnick","year":"2018","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0905","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00259-020-04727-9","article-title":"Incremental diagnostic value of [(18)F]tetrafluoroborate PET-CT compared to [(131)I]iodine scintigraphy in recurrent differentiated thyroid cancer","volume":"47","author":"Dittmann","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0910","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13550-020-0610-x","article-title":"(68)Ga-PSMA PET\/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with (177)Lu-PSMA-617","volume":"10","author":"de Vries","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.diii.2021.04.004_bib0915","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13550-020-00720-3","article-title":"Gallium-68 prostate-specific membrane antigen ([(68)Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study","volume":"10","author":"Lawhn-Heath","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.diii.2021.04.004_bib0920","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s12032-020-01427-0","article-title":"The prostate-specific membrane antigen (PSMA)-targeted radiotracer 18F-DCFPyL detects tumor neovasculature in metastatic, advanced, radioiodine-refractory, differentiated thyroid cancer","volume":"37","author":"Santhanam","year":"2020","journal-title":"Med Oncol"},{"key":"10.1016\/j.diii.2021.04.004_bib0925","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s11547-014-0474-0","article-title":"Accuracy of MRI for the diagnosis of metastatic cervical lymphadenopathy in patients with thyroid cancer","volume":"120","author":"Chen","year":"2015","journal-title":"Radiol Med"},{"key":"10.1016\/j.diii.2021.04.004_bib0930","doi-asserted-by":"crossref","first-page":"438","DOI":"10.5152\/dir.2014.14008","article-title":"Clinical applications of PET\/MRI: current status and future perspectives","volume":"20","author":"Nensa","year":"2014","journal-title":"Diagn Interv Radiol"},{"key":"10.1016\/j.diii.2021.04.004_bib0935","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40644-016-0096-y","article-title":"Impact of combined FDG PET\/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer","volume":"16","author":"Hempel","year":"2016","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0940","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00259-015-3195-2","article-title":"[(18)F]FDG PET\/CT outperforms [(18)F]FDG PET\/MRI in differentiated thyroid cancer","volume":"43","author":"Vrachimis","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0945","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00259-013-2580-y","article-title":"Detection and quantification of focal uptake in head and neck tumors: (18)F-FDG PET\/MR versus PET\/CT","volume":"41","author":"Varoquaux","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.diii.2021.04.004_bib0950","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1007\/s00259-020-04938-0","article-title":"Comparison of simultaneous 18F-2-[18F] FDG PET\/MR and PET\/CT in the follow-up of patients with differentiated thyroid cancer","volume":"47","author":"Klain","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Diagnostic and Interventional Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568421000851?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211568421000851?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T17:36:27Z","timestamp":1761932187000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211568421000851"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":95,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2211568421000851"],"URL":"https:\/\/doi.org\/10.1016\/j.diii.2021.04.004","relation":{},"ISSN":["2211-5684"],"issn-type":[{"value":"2211-5684","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PET\/CT in the management of differentiated thyroid cancer","name":"articletitle","label":"Article Title"},{"value":"Diagnostic and Interventional Imaging","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diii.2021.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radiologie. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}